The stock of Brainstorm Cell Therapeutics, Inc (BCLI) has seen a 13.86% increase in the past week, with a 28.49% gain in the past month, and a -5.35% decrease in the past quarter. The volatility ratio for the week is 8.31%, and the volatility levels for the past 30 days are at 11.43% for BCLI. The simple moving average for the past 20 days is 5.70% for BCLI’s stock, with a -48.06% simple moving average for the past 200 days.
Is It Worth Investing in Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) Right Now?
Additionally, the 36-month beta value for BCLI is 0.26. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BCLI is 4.43M and currently, short sellers hold a 2.11% ratio of that float. The average trading volume of BCLI on January 22, 2025 was 107.49K shares.
BCLI) stock’s latest price update
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) has experienced a rise in its stock price by 21.69 compared to its previous closing price of 1.89. However, the company has seen a gain of 13.86% in its stock price over the last five trading days. prnewswire.com reported 2024-12-30 that NEW YORK, Dec. 30, 2024 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. Dear Valued Shareholders, 2024 has been a very productive year for BrainStorm Cell Therapeutics, defined by remarkable milestones and achievements that have brought us closer to our mission of delivering groundbreaking therapies for neurodegenerative diseases.
Analysts’ Opinion of BCLI
Many brokerage firms have already submitted their reports for BCLI stocks, with Maxim Group repeating the rating for BCLI by listing it as a “Buy.” The predicted price for BCLI in the upcoming period, according to Maxim Group is $12 based on the research report published on February 04, 2021 of the previous year 2021.
Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $6 in the report published on December 19th of the previous year.
BCLI Trading at 30.92% from the 50-Day Moving Average
After a stumble in the market that brought BCLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.66% of loss for the given period.
Volatility was left at 11.43%, however, over the last 30 days, the volatility rate increased by 8.31%, as shares surge +2.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.90% upper at present.
During the last 5 trading sessions, BCLI rose by +13.86%, which changed the moving average for the period of 200-days by -77.76% in comparison to the 20-day moving average, which settled at $2.1800. In addition, Brainstorm Cell Therapeutics, Inc saw 1.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCLI starting from Lebovits Chaim, who purchase 1,836 shares at the price of $3.43 back on Oct 01 ’24. After this action, Lebovits Chaim now owns 80,960 shares of Brainstorm Cell Therapeutics, Inc, valued at $6,292 using the latest closing price.
Lebovits Chaim, the President & CEO of Brainstorm Cell Therapeutics, Inc, purchase 22,000 shares at $0.23 during a trade that took place back on Sep 30 ’24, which means that Lebovits Chaim is holding 1,186,865 shares at $5,016 based on the most recent closing price.
Stock Fundamentals for BCLI
Current profitability levels for the company are sitting at:
- -95.74 for the present operating margin
- -0.4 for the gross margin
The net margin for Brainstorm Cell Therapeutics, Inc stands at -102.36. The total capital return value is set at 2.63.
Based on Brainstorm Cell Therapeutics, Inc (BCLI), the company’s capital structure generated -0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -13.47. The debt to equity ratio resting at -0.14. The interest coverage ratio of the stock is -144.65.
Currently, EBITDA for the company is -16.93 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 99.22. The receivables turnover for the company is 3.48for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.05.
Conclusion
In conclusion, Brainstorm Cell Therapeutics, Inc (BCLI) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
